SCHEMBL24310146

SCHEMBL24310146

CCCc1c(Oc2cccc(N3CCN(C)CC3)c2Cl)nc(NS(=O)(=O)c2cnn(C)c2)nc1-c1ccccc1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD9 Q9H8M2 3/20 0.36
▸ HTR1A P08908 3/20 0.34
▸ HTR7 P34969 2/20 0.34
▸ EGFR P00533 6/20 0.34
▸ HTR2A P28223 3/20 0.33
▸ HTR2C P28335 2/20 0.33
▸ DRD2 P14416 2/20 0.33
▸ DRD4 P21917 2/20 0.33
▸ BRD7 Q9NPI1 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ HTR6 P50406 4/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ ADRA2A P08913 1/20 0.32
▸ DRD1 P21728 1/20 0.32
▸ DRD5 P21918 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566988 1.00 BRD9 (0.36) BRD9HTR1AHTR7EGFRHTR2A
SCHEMBL29567132 0.94 HTR1A (0.36) BRD9HTR1AHTR7EGFRHTR2A
SCHEMBL24310080 0.94 HTR1A (0.36) BRD9HTR1AHTR7EGFRHTR2A
SCHEMBL29566944 0.91 HTR1A (0.36) HTR1AHTR7EGFRHTR2AHTR2C
SCHEMBL26808935 0.91 HTR1A (0.36) HTR1AHTR7EGFRHTR2AHTR2C
SCHEMBL26811586 0.91 BRD9 (0.33) BRD9HTR1AEGFRHTR2AHTR2C
SCHEMBL29566582 0.90 HTR1A (0.36) HTR1AHTR7EGFRHTR2AHTR2C
SCHEMBL24310703 0.90 HTR1A (0.36) HTR1AHTR7EGFRHTR2AHTR2C
SCHEMBL24309981 0.90 HTR1A (0.33) HTR1AHTR7EGFRHTR2AHTR2C
SCHEMBL29566794 0.90 HTR1A (0.33) HTR1AHTR7EGFRHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B BRD9 2385/4885HTR1A 4018/4885HTR7 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback